ARTV
NASDAQ · Biotechnology
Artiva Biotherapeutics Inc
$4.03
+0.16 (+4.13%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 15.19M | 14.43M | 14.50M |
| Net Income | -2,971,681 | -2,421,627 | -2,767,986 |
| EPS | — | — | — |
| Profit Margin | -19.6% | -16.8% | -19.1% |
| Rev Growth | -5.2% | +14.0% | +5.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 16.91M | 16.72M | 14.95M |
| Total Equity | 51.52M | 53.96M | 56.37M |
| D/E Ratio | 0.33 | 0.31 | 0.27 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -2,996,612 | -2,990,686 | -3,421,626 |
| Free Cash Flow | -2,370,454 | -1,604,262 | -1,971,320 |